Summary Our study has demonstrated that in contrastenhanced multi-detector computed tomography (MDCT)-based bone density measurements, the scan delay time after contrast agent administration is a statistically significant variable for the derivation of quantitative computed tomography (QCT)-equivalent bone mineral density (BMD) values. Introduction Earlier investigators have proposed to derive QCT-equivalent BMD values from contrast-enhanced MDCT scans by using a merely density-based conversion equation. The purpose of this study was to investigate whether the scan delay after intravenous (IV) contrast agent administration might affect BMD values derived in this way. Methods A retrospective data analysis was performed on 198 subjects who underwent standardized biphasic MDCT. Average densities values (in Hounsfield units) of lumbar vertebral bodies 1 to 3 (L1-L3) were compared between phases I and II of the biphasic MDCT scan. Furthermore, QCT-equivalent BMD (BMD QCT ) values were calculated using a previously published conversion equation. Results Paired t-test analysis revealed that IV contrast agent administration leads to a statistically significant increase (8.6 %; p<0.0001) in overall density of L1-L3 from phases I to II. Moreover, comparison of BMD QCT values between phases I and II reveals a change from osteoporotic to osteopenic in 4.5 % of the study population and from osteopenic to normal for 11.1 % of the subjects. Furthermore, it was revealed that the density increase from phases I to II shows a weak, yet statistically significant (p<0.001) age dependency.
Introduction
Osteoporosis is a chronic systemic skeletal disorder that is characterized by low bone mass and deterioration of bone microarchitecture. As with other chronic diseases, such as hypertension and diabetes, the onset of osteoporosis and progression may go unrecognized for many years. However, once a clinically obvious event such as a hip fracture has occurred, the substantial and fatal burden of this silent epidemic, on the individual and on the public health care system, becomes apparent.
The mortality rate of patients suffering osteoporotic hip fractures is 20 % within the first year [1] , and in the first 3-6 months, 20-30 % of the estimated deaths are causally related to the fracture event itself [2] . Moreover, with the exception of lung cancer, osteoporosis accounts for more disability-adjusted life years lost than any other malignant neoplastic disease [3] . Thus, it is of utmost importance to identify patients at high risk and to prevent the first fracture event, which by itself is a single important risk factor for the occurrence of future fractures [4] .
In clinical practice, aside from the frequently used dualenergy X-ray absorptiometry and quantitative ultrasound, quantitative computed tomography (QCT) is sometimes used for the diagnosis and monitoring of osteoporosis by assessing the volumetric bone mineral density (BMD). QCT of the lumbar spine, which ideally is performed with an external bone density calibration phantom, is done as an unenhanced scan of the midvertebral section of lumbar vertebral bodies 1, 2, and 3 (L1, L2, and L3), aligned parallel to the orientation of the upper and lower endplates.
However, as clinically indicated multi-detector computed tomography (MDCT) is among the most commonly used imaging methods, it has recently been proposed to assess QCT-equivalent volumetric BMD from these MDCT scans, thereby dispensing the need for additional specific QCT scans.
Previous studies investigating these non-QCT-derived BMD values calculated from MDCT scans-without [5] [6] [7] and with intravenous (IV) [8] [9] [10] [11] [12] administration of a contrast agent-have all proposed the use of a density-based conversion equation. Although some investigators discussed the influence of an IV contrast agent as a limitation, to our knowledge, no MDCT study has yet explicitly and systematically investigated this issue.
Thus, the aim of this study was to evaluate the influence of IV contrast agent administration on BMD measured in L1-L3 and to investigate whether or not this influence varies with the time delay between the CT scans. For this purpose, a retrospective data analysis was performed on biphasic abdominal MDCT scans obtained with standardized contrast agent injection protocols and standardized scan time delays.
Methods

Subjects
Subjects examined between 1 January 2011 and 1 January 2012 were retrospectively identified from our digital archive system (RIS-PACS) using the following query: (1) scan on one predefined CT scanner, (2) abdominal scan, (3) standardized biphasic protocol, and (4) no known oncological disease as reported in the patient's history stored with the CT dataset. Upon admission to our hospital-in accordance with the World Medical Association Declaration of Helsinki-each patient had given signed informed consent that acquired images, and other data may be used for scientific evaluation. Furthermore, the study design and analysis were fully approved by the institutional review board (processing number EA1/144/12).
Imaging
All scans were performed on the same 64 multi-detector-row MDCT scanner (Toshiba Aquilion 64; Otawara Japan). As the scans were routine abdominal scans-and not QCT scans-no external calibration phantom was placed underneath the subjects. The subjects were positioned supine with the arms lifted above the head. After automatic IV injection of 120 ml of contrast agent (Xenetix 350; Guerbet Group, France), scanning was performed using one of two standardized biphasic CT protocols (protocols 1 and 2, see Table 1 ) with preset delay times and contrast agent injection protocols. Both protocols used a tube voltage of 120 kVp with an automatically dose-modulated tube current and a rotation time of 0.5 s. The axial slice thickness was 0.5 mm (thin slice) and secondary multiplanar reconstructions-with an axial slice thickness of 5 mm (thick slice) and standard sagittal and coronal views-were generated.
Protocol 1 is frequently used in our institution for kidney imaging (e.g., before living donation) and for the diagnosis of bowel ischemia or abdominal bleedings. For protocol 1, the contrast agent administration started with a flow of 2 ml/s, injecting 40 ml over 20 s, and then, the flow was increased to 3.7 ml/s, and the remaining 80 ml was injected. Following the beginning of contrast agent injection, the firstphase images (phase I) were acquired after 40 s, and the second-phase images (phase II) were acquired after 120 s.
Protocol 2 is frequently used for the initial CT scan in patients with a nonspecific mass of the liver or pancreas. For protocol 2, the contrast agent administration was performed with a continuous flow of 4 ml/s for the entire 120 ml of contrast agent. Phase I was acquired after a visual arterial sure start, and 30 s after the end of phase I, acquisition of phase II began.
Image analysis
Image analysis was performed with our institutional PACS software (Centricity RIS-i 4.2 Plus; General Electric Healthcare Company, USA). Within the axial thick slice (5 mm) dataset, for both phases I and II, the same midvertebral slices of lumbar vertebral bodies 1, 2, and 3 (L1, L2, and L3) were visually identified, using the reconstructed sagittal views as guidance, aiming to find the best compromise between the exact anatomical midvertebral section and the non-anatomical axial CT image.
Vertebral bodies with fractures, osteolytic/osteoblastic lesions and hemangiomas were excluded from further analysis. Then, for each phase, an oval region of interest (ROI) was manually placed within the anterior two thirds of each of the first three lumbar vertebral bodies, carefully avoiding the cortical bone and the vertebral venous plexus (see Fig. 1 ). The average Hounsfield units (HU) in the respective ROIs were noted as the density measures for L1, L2, and L3.
Data and statistical analysis
For each individual subject, the average HU values of the ROIs in L1, L2, and L3 were used to calculate the overall mean HU density value (BMD MDCT ) and the standard deviation (SD) of L1 to L3. From these values, absolute and percentage differences between phases I and II were calculated.
Absolute difference :
In addition, we calculated QCT-equivalent BMD values (BMD QCT ) using the conversion equation (BMD QCT =(0.96× BMD MDCT )−20.9 mg/ml) proposed by Bauer et al. [10] . According to these BMD QCT values in each phase, every subject was then classified as normal (>120 mg/ml), osteopenic (≤120-mg/ml), or osteoporotic (<80 mg/ml). These cutoff levels have been proposed by the American College of Radiology [13] and by Felsenberg and Gowin [14] .
In our statistical analysis, we first tested if the protocol type or gender had a significant impact on changes in BMD MDCT between phases I and II. For this purpose, the subjects were grouped into four subgroups (protocol 1+male/protocol 1+ female/protocol 2+male/protocol 2+female), and an ANOVA (including post hoc comparisons between the groups) test was performed to identify significant differences between these four subgroups. In addition, we also performed an ANOVA to test for age differences between all four groups to rule out this possible bias in the group comparison. As no significant differences between these four subgroups were found using the whole dataset, we subsequently examined the correlation (using Pearson's test) between age and BMD MDCT and ΔBMD MDCT , respectively. Using a paired t test, we then tested for significant differences in BMD MDCT values between phases I and II. All statistical analyses and tests were performed using PRISM® (version 5.0a, GraphPad Software; San Diego, USA).
Results
Subjects and image analysis
The data query retrieved 198 subjects (M/F=107/91, mean age ± SD=59.7±15.0 years) who were eligible for this retrospective data analysis. Due to fractures, osteolytic/osteoblastic lesions, and hemangiomas, 19 vertebral bodies had to be excluded from further analysis, one vertebral body in 11 subjects and two vertebral bodies in 4 subjects. In the remaining 183 subjects, all vertebral bodies were included in the analysis. Thus, a total of 575 vertebral bodies with 1,150 ROIs were used for our data analysis. A MDCT examination according to protocol 1 was performed in 60 male (mean age ± SD=59.7±13.5) and 51 female (mean age ± SD=61.2±15.6) subjects. Protocol 2 was performed in 47 male (mean age ± SD=58.6±14.0) and 40 female (mean age ± SD=59.1±17.5) subjects. Age differed not significantly between these groups in an ANOVA (p=0.84) including post-comparisons.
Influence of protocol type and gender First, we tested for influences of gender and protocol type on ΔBMD MDCT . Comparing the four subgroups in an ANOVA revealed no significant overall differences (p=0.124), and post hoc tests between the groups also showed no statistical significant difference. Thus, we excluded gender and protocol type as variables from further analysis.
Influence of age Subsequently, we tested for an association between BMD MDCT values and age. Irrespective of the phase, BMD MDCT showed a highly significant, strong, negative correlation with age (r=−0.6; p<0.0001), reflecting the overall loss of bone density with aging (see Fig. 2 ). Interestingly, however, there was also a highly significant, yet weak, positive correlation between Fig. 2 In the upper row for each phase, the correlation of BMD MDCT (measured in HU) with age is depicted. In the lower row, the correlation between ΔBMD with age and phase I is depicted ΔBMD MDCT and age (r=0.2; p<0.001; see Fig. 2 ), indicating that with every life year, ΔBMD MDCT increases by a factor of 0.2 HU. This means that for an 80-year-old subject, there would be a solely age-dependent increase of up to 16 HU between phases I and II, as compared to an increase of only 4 HU in a 20-year-old subject.
Phases I and II
The mean values (with SD) of BMD MDCT for each phase are given in Table 2 . As gender and protocol type had no statistically relevant influence, overall BMD MDCT for phase I was calculated as 160.0±4.1 HU, and overall BMD MDCT for phase II was 173.9±3.9 HU.
Strikingly, however, when comparing the BMD MDCT values of the two scan phases with each other, a highly significant density increase from phases I to II (p<0.0001) was found. For some outliers, this increase was as high as 101 HU or 157 %. Overall, however, the statistically significant increase from phases I to II was approximately 13.8±1.0 HU, corresponding to an 8.6 % increase compared to the density of phase I (see Table 2 ).
Moreover, when comparing the BMD QCT values from the two scan phases, for nine subjects (4.5 % of the study population) who were classified as osteoporotic in phase I, the density increase was so high that their BMD QCT status changed to osteopenic, and 22 subjects (11.1 % of the study population) who were classified as osteopenic in phase I showed normal BMD QCT values in phase II (see Fig. 3 ).
Discussion
As MDCT is one of the most widely used imaging techniques, several recent studies [5] [6] [7] [8] [9] [10] [11] [12] have explored the use of these non-QCT datasets for deriving QCT-equivalent volumetric BMD values. Especially, oncological patients, whose treatment is a risk factor for secondary osteoporosis [15, 16] , would benefit from such an approach, as they frequently undergo MDCT for staging.
Hopper et al. [8] were one of the first investigators to propose the use a conversion equation to obtain reliable BMD values, and interestingly, investigators from Hopper et al. in 2000 to Baum et al. [12] , who published one of the most recent studies in this field in 2012, all used a merely density-based conversion equation, although most studies were based on contrast-enhanced MDCT scans. Each used conversion equation has the following basic form:
disregarding possible time-dependent changes that might occur due to the circulation and accumulation of a contrast agent. Effects of the contrast agent administration on BMD values have, in fact, been discussed as limitations but have not been investigated systematically. In their study of 26 patients, Hopper et al. [8] , for instance, conclude that there is no statistically significant difference (p=0.085) between QCT performed from non-contrast and contrast-enhanced MDCT scans; however, they provide no detailed information on contrast agent administration and scan delay time. Link et al. [9] performed a study on 50 subjects using QCT and contrast-enhanced MDCT scans of the lumbar spine. All subjects received a standardized contrast agent dose of 140 ml (Xenetix 350) at a flow rate of 3 ml/s. The scan delay time was set to 70 s. A similar study by Bauer et al. [10] included 40 subjects; however, in this study, the dose of a contrast agent was based on body weight (1 ml/kg of body weight), and scanning was performed with a delay of 80 s.
These two studies as well as the QCT studies published by Baum et al. [11, 12] derive their conversion equations through mere linear fitting of QCT and MDCT density values without taking the amount of contrast agent or the scan delay time into account. Thus, the aim of our study was to evaluate the effect of IV contrast agent administration on the measured bone density and to discuss possible diagnostic limitations of non-QCT-derived bone density determinations. In accordance with previously published studies [9, 17, 18] , we found no statistically significant difference between male and female subjects. As for age, our results show that measured bone density decreases significantly with age. Lenchik et al. found the same inverse association between age and BMD in 762 subjects [5] .
Interestingly, however, our results also show that aging is associated with an increase in ΔBMD MDCT of L1-L3, suggesting that the bone density difference between both acquisition phases is, on average, larger in older subjects. Two hypotheses may explain this observation: (1) as the actual bone density in older subjects decreases, the influence of IV contrast agent differences may become larger, and the density increase observed is only relative, and (2) regardless of actual bone density, aging is associated with an increased intraosseous perfusion of vertebral bodies. The latter hypothesis, however, contradicts various magnetic resonance imaging (MRI) studies of bone marrow perfusion, which showed bone marrow perfusion to decrease with age [19, 20] . Thus, our first hypothesis appears stronger. With regard to our first hypothesis, the results of previous MRI studies that show a decrease in bone marrow perfusion due to osteopenia and osteoporosis [21] [22] [23] are not contrary to our hypothesis, because one must keep in mind that in MDCT-derived density measures, the actual loss in bone density directly influences the overall density measures.
In other words, in MDCT as compared to MRI, the mere density of the bone itself accounts for most of the overall measured density. Therefore, density changes caused by IV contrast agent administration are less detectable in dense bone as compared to sparse bone, explaining why our results show that with increasing age, ΔBMD MDCT seems to increase as well.
Besides identifying possible effects of gender and age, however, our primary aim was to show whether a timedependent effect in measured bone density is quantifiable after IV contrast administration, and our results show that such an effect exists. In a MDCT scan, the steady accumulation of contrast agent in L1 to L3 over time causes a statistically highly significant (p<0.0001) increase in the overall bone density, mimicking higher BMD MDCT values in phase II as compared to phase I.
To demonstrate how this effect has an impact on the derivation of QCT-equivalent BMD values, we decided to generate BMD QCT values for both phases by using one of the above-described conversion equations. As the study by Bauer et al. [10] and our study are MDCT studies performed on axial slices of L1 to L3, we chose the equation they [10] . Based on these BMD QCT values, the subjects were then grouped as osteoporotic, osteopenic, or normal propose: BMD QCT =(0.96×BMD MDCT )−20.9 mg/ml. These BMD QCT values, for each phase, were then used to classify each subject as either osteoporotic, osteopenic, or normal. Our results (see Fig. 3 ) demonstrate that for 31 of the 198 subjects (15.6 %), the time-dependent accumulation of contrast agent in L1-L3 causes a statistically significant shift in group assignments between phases I and II. In other words, between the two time points of the MDCT scan, the BMD QCT value changes from osteoporotic to osteopenic for 4.5 % of the study population and from osteopenic to normal for 11.1 % of the subjects. Thus, we demonstrated that the scan delay time is an important variable in the MDCT-to-QCT conversion and should be incorporated in the MDCT-to-QCT conversion equations.
A major limitation of our study is that due to the retrospective study design, a dedicated bone density phantom was not used. Furthermore, it would have been desirable to include a preinjection, in other word, a non-contrastenhanced scan into the data analysis. However, our primary aim was not to present another conversion formula but to demonstrate that administration of an IV contrast agent is not a negligible factor. Our results show that a mere densitybased formula is not sufficient to generate QCT-equivalent BMD values from contrast-enhanced MDCT scans.
Another limitation of our study is that we evaluated two different CT scan protocols. However, when evaluating the different scan time parameters in the two protocols and comparing these with published data, this limitation is negligible. In detail, protocol 1 had a delay of 80 s between phases II and I, with phase I starting 40 s and phase II starting 120 s after contrast agent injection. Protocol 2 had a delay of 30 s between phases II and I, with phase I starting after a visual arterial sure start. Despite missing individual blood circulation times, it may be expected from known average blood circulation times that the injected contrast agent bolus reaches a peak in the aortic circulation system after an average of 20 to 30 s, and the visual sure start of phase I (protocol 2) is started. Thus, it may further be presumed that due to the fixed delay of 30 s, phase II of protocol 2 was acquired at approximately 50 to 60 s after contrast agent injection.
Concerning the statistically significant difference between phases I and II in both protocols, we thus hypothesize that within the vertebral body, a statistically significant increase in a contrast agent (blood perfusion) takes place between 40 s (phase I, protocol 1) and 60 s (phase II, protocol 2) after injection. This hypothesis corresponds well to results of MRI-based perfusion studies, such as those published by Griffith et al., Biffar et al., and Chen et al. [22, 24, 25] . Although these studies focused on the interpretation of perfusion indices such as maximum enhancement and enhancement slope, the data confirm what our hypothesis suggests. Within the first 60 s after contrast agent injection, the enhancement slopes for bone marrow perfusion reach their highest values.
Beyond these results, our study shows that the time course of contrast agent enhancement results in statistically significant differences in density values. In the studies of Baum et al. [11, 12] and Link et al. [9] , scanning was performed 70 s after contrast agent injection, whereas in the study published by Bauer et al. [10] , scanning was performed 80 s after contrast agent injection. Based on our results, we can assume that these delay times resulted in homogenous bone marrow perfusion. Yet age-or BMD-dependent variations in bone marrow perfusion, as described in the second section of this discussion, remain neglected. Thus, the recent proposal to use a mere density-based conversion equation to derive QCT-equivalent volumetric BMD values from MDCT datasets (after IV contrast agent administration) will result in inaccurate estimates. To partially overcome these limitations or, in other words, to reduce the amount of different variables for future studies, assuring equal scan conditions, an approach that generates individual conversion equations for each patient-rather than general population-based conversion equations-might be helpful.
In conclusion, our study has demonstrated that in MDCTbased bone density measurement, the scan delay time after contrast agent administration is a statistically significant variable for the derivation of QCT-equivalent BMD values. Furthermore, in accordance with MRI-based bone perfusion studies, our results suggest that the actual age-dependent BMD value (normal vs. osteopenic vs. osteoporotic) is another variable that needs to be considered.
